FDA Approved Drugs for Cardiology/Vascular Diseases

Drugs Approved in 2017

Bevyxxa (betrixaban); Portola Pharmaceuticals; For the the prophylaxis of venous thromboembolism, Approved June 2017

Drugs Approved in 2016

Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016

Yosprala (aspirin and omeprazole); Aralez Pharmaceuticals; For the prevention of cardiovascular and cerebrovascular events, Approved September 2016

Drugs Approved in 2015

Corlanor (ivabradine); Amgen; For the treatment of chronic heart failure, Approved April 2015

Entresto (sacubitril and valsartan); Novartis; For the treatment of chronic heart failure, Approved July 2015

Kanuma (sebelipase alfa); Alexion; For the treatment of Lysosomal Acid Lipase (LAL) deficiency, Approved December 2015

Kengreal (cangrelor) ; The Medicines Company; For reducing periprocedural thrombotic events, Approved June 2015

Praluent (alirocumab); Sanofi Aventis; For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, Approved July 2015

Prestalia (perindopril arginine and amlodipine besylate); Symplmed Pharmaceuticals; For the treatment of hypertension, Approved January 2015

Repatha (evolocumab) ; Amgen; For the treatment of high cholesterol, Approved August 2015

Savaysa (edoxaban); Daiichi Sankyo; For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015

Uptravi (selexipag); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved December 2015

Drugs Approved in 2014

Epanova (omega-3-carboxylic acids); AstraZeneca; For the treatment of severe hypertriglyceridemia, Approved May 2014

Zontivity (vorapaxar); Merck; For the reduction of thrombotic cardiovascular events, Approved May 2014

Drugs Approved in 2013

Adempas (riociguat); Bayer Healthcare Pharmaceuticals; For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension, Approved October 2013

Kynamro (mipomersen sodium); Genzyme; For the treatment of homozygous familial hypercholesterolemia, Approved January 2013

Liptruzet (ezetimibe and atorvastatin); Merck; For the treatment of hyoerlipidemia, Approved May 2013

Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013

Opsumit (macitentan); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved October 2013

Varithena (polidocanol injectable foam); BTG plc; For the treatment of varicose veins, November 2013

Drugs Approved in 2012

Eliquis (apixaban); Bristol-Myers Squibb; For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation, Approved December 2012

Juxtapid (lomitapide); Aegerion Pharmaceuticals; For the treatment of homozygous familial hypercholesterolemia, Approved December of 2012

Vascepa (icosapent ethyl); Amarin Pharmaceuticals; For the treatment of hypertriglyceridemia, Approved July of 2012

Drugs Approved in 2011

Brilinta (ticagrelor); AstraZeneca; For the reduction of thrombotic events in patients with acute coronary syndrome, Approved July 2011

Edarbi (azilsartan medoxomil); Takeda; For the treatment of hypertension, Approved February 2011

Edarbyclor (azilsartan medoxomil and chlorthalidone); Takeda; For the treatment of hypertension, Approved December of 2011

Xarelto (rivaroxaban); Bayer; For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011

Xarelto (rivaroxaban); Janssen Pharmaceuticals; For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011

Drugs Approved in 2010

Amturnide (aliskiren + amlodipine + hydrochlorothiazide); Novartis; For the treatment of uncontrolled hypertension, Approved December 2010

Pradaxa (dabigatran etexilate mesylate); Boehringer Ingelheim; For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010

Tekamlo (aliskiren + amlodipine); Novartis; For the treatment of hypertension, Approved August 2010

Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide); Daiichi Sankyo; For the treatment of hypertension, Approved July 2010

Drugs Approved in 2009

Adcirca (tadalafil); Eli Lilly; For the treatment of pulmonary arterial hypertension, Approved May 2009

Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics; For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009

Efient (prasugrel); Eli Lilly; for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009

Livalo (pitavastatin); Kowa Company; For the treatment of primary hyperlipidemia and mixed dyslipidemia, Approved August 2009

Multaq (dronedarone); Sanofi-aventis; For the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter, Approved July 2009

Tyvaso (treprostinil); United Therapeutics; For the treatment of pulmonary arterial hypertension, Approved July 2009

Drugs Approved in 2008

Cleviprex (clevidipine); The Medicines Company; For the treatment of hypertension when oral therapy is not feasible or not desirable, Approved August 2008

Trilipix (fenofibric acid); Abbott Laboratories; For the treatment of dyslipidemia, hypertriglyceridemia and hyperlipidemia, Approved December 2008

Drugs Approved in 2007

Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo; For the treatment of hypertension, Approved September 2007

Fenofibrate; LifeCycle Pharma; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007

Letairis (ambrisentan); Gilead; For the treatment of pulmonary arterial hypertension, Approved June 2007

Soliris (eculizumab); Alexion; For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007

Tekturna (aliskiren); Novartis; For the treatment of hypertension, Approved March 2007

Drugs Approved in 2006

Ranexa (ranolazine); CV Therapeutics; For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006

Drugs Approved in 2005

BiDil (isosorbide dinitrate/hydralazine hydrochloride); NitroMed; For the treatment of heart failure in black patients, Approved June, 2005

Drugs Approved in 2004

Caduet (amlodipine/atorvastatin); Pfizer; For the treatment of hypertension, chronic stable angina and vasospastic angina, Approved January 2004

Drugs Approved in 2003

Crestor (rosuvastatin calcium); AstraZeneca; For the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia, Approved August 2003

Levitra (vardenafil); Bayer, GlaxoSmithKline; For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003

Drugs Approved in 2002

Altocor (lovastatin) Extended-Release Tablets; Andrx; Oral tablets for the adjuctive treatment of hypercholesterolemia, Approved June 2002

Benicar; Daiichi Sankyo; Oral tablet for the treatment of hypertension, Approved April 2002

Imagent (perflexane lipid microspheres); Alliance Pharmaceutical; Ultrasound contrast agent for improved imaging of the heart, Approved June 2002

Inspra (eplerenone tablets); Pharmacia & Upjohn; Oral tablets for the treatment of high blood pressure., Approved September 2002

Plavix (clopidogrel bisulfate); Sanofi-aventis; For the treatment of acute coronary syndrome, Approved February 2002

Remodulin (treprostinil); United Therapeutics; For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002

Drugs Approved in 2001

Advicor (extended-release niacin/lovastatin); Kos Pharmaceuticals; For the treatment of cholesterol disorders, Approved December 2001

Diovan (valsartan); Novartis; Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)

Natrecor (nesiritide); Scios; For the treatment of patients with acutely decompensated congestive heart failure, Approved August 2001

Teveten (eprosartan mesylate plus hydrochlorothiazide); Unimed Pharmaceuticals; Tablets for the treatment of hypertension, Approved November 2001

Tricor (fenofibrate); Abbott Laboratories; For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertriglyceridemia, Approved September 2001

Drugs Approved in 2000

Angiomax (bivalirudin); The Medicines Company; For patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA), Approved December 2000

Argatroban Injection; Texas Biotechnology Corporation, SmithKline Beecham; Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000

Atacand (candesartan cilexetil); AstraZeneca; For the treatment of hypertension, Approved September 2000

Betapace AF Tablet; Berlex Laboratories; For treatment of the irregular heartbeats in patients with atrial fibrillation, Approved February 2000

Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories; For the reduction of high blood pressure, Approved January 2000

Innohep (tinzaparin sodium) injectable; DuPont Merck Pharmaceutical Company; For the treatment of acute symptomatic deep vein thrombosis, Approved July 2000

Lescol XL (fluvastatin sodium) tablet, extended release; Novartis; For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000

Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim; For the treatment of hypertension, Approved November 2000

Nitrostat (nitroglycerin) Tablets; Parke-Davis; For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease., Approved May 2000

Drugs Approved in 1999

Lescol (fluvastatin sodium) capsules, Rx; Novartis; Treatment for the reduction of triglycerides, Approved June 1999

Mevacor (lovastatin) tablets; Merck; Treatment for primary prevention of coronary heart disease, Approved March 1999

Niaspan; Kos Pharmaceuticals; Niacin extended-release tablets, October 28, 1999

Drugs Approved in 1998

Agrylin (anagrelide HCL); Roberts Pharmaceutical; Treatment for Thrombocythemia, Approved December 1998

CellCept; Roche; Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998

Diovan HCT (valsartan); Novartis; Treatment for hypertension, Approved March 1998

Integrilin; COR Therapeutics, Key Pharmaceuticals; Injection of eptifibatide, Approved May 1998

Micardis (telmisartan); Boehringer Ingelheim; Treatment for Hypertension, Approved November 1998

Rythmol; Knoll Pharmaceutical; Treatment for paroxysmal atrial fibrillation, Approved January 1998

Tiazac (diltiazem hydrochloride); Forest Laboratories; Treatment for chronic stable angina, Approved February 1998

Tricor (fenofibrate); Abbott Laboratories; Treatment for very high triglyceride levels, Approved February 1998

Viagra; Pfizer; Treatment for impotence, Approved March 1998

Drugs Approved in 1997

Baycol (cerivastatin sodium); Bayer; Treatment for high cholesterol, Approved June 1997; withdrawn 8/8/01

Captopril and hydrochlorotiazide; Mylan Laboratories; Treatment for hypertension, Approved May 1997

Cardizem (R) (Diltiazem HC1 for injection) Monvial (R); Hoechst Marion Roussel; Delivery system for Monovial, Approved September 1997

Corlopam; Neurex; Treatment for severe high blood pressure, Approved September 1997

Diovan (valsartan); Ciba Pharmaceuticals; Treatment for hypertension, Approved January 1997

DynaCirc CR; Novartis; Treatment for hypertension, Approved February 1997

EDEX; Schwarz Pharma; Treatment for erectile dysfunction, Approved June 1997

Lescol (fluvastatin sodium); Novartis; Treatment for coronary atherosclerosis, Approved September 1997

Lexxel (enalapril maleate-felodipine ER); Astra Merck; Treatment for hypertension, Approved January 1997

Microzide (hydrochlorothiazide); Watson Pharmaceuticals; Treatment for mild-to moderate hypertension, Approved January 1997

Normiflo; Wyeth; Treatment for deep venous thrombosis, Approved May 1997

Pentoxifylline; Faulding, Mylan Laboratories; Generic equivalent of Trental, Approved July 1997

Pindolol; Teva Pharmaceutical; Generic equivalent of Visken, Approved April 1997

Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb; Treatment for cardiac atherosclerotic events, Approved November 1997

Posicor; Roche; Treatment for hypertension and chronic stable angina pectoris, Approved June 1997

ReoPro; Centocor Ortho Biotech; Treatment for cardiac ischemic complications, Approved November 1997

REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals; Generic equivalent of Pergonal, Approved February 1997

Teveten (eprosartan mesylate); SmithKline Beecham; Treatment for hypertension, Approved December 1997

Verapamil; IVAX; Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997

Warfarin Sodium tablets; Barr Laboratories; Generic equivalent of Coumadin, Approved March 1997

Zocor; Merck; Treatment for high cholesterol, Approved November 1997

Drugs Approved in 1996

Covera-HS (verapamil); GD Searle, Alza; Treatment for hypertension and angina, Approved January 1996

Lipitor (atorvastatin calcium); Pfizer; For the prevention of cardiovascular disease and treatment of hyperlipidemia and dyslipidemia, Approved December 1996

Mavik (trandolapril); Knoll Pharmaceutical; Treatment for hypertension, Approved May 1996

Muse; Vivus; Treatment for impotence, Approved October 1996

Pravachol (pravastatin sodium); Bristol-Myers Squibb; Treatment for cholesterol-lowering, Approved July 1996

Pravachol (pravastatin sodium); Bristol-Myers Squibb; Treatment for heart disease, Approved April 1996

ProAmatine (midodrine); Roberts Pharmaceutical; Treatment for hypotension, Approved September 1996

Procanbid (procainamide hydrochloride extended-release tablets); Warner-Lambert; Treatment for ventricular arrhythmias, Approved January 1996

Retavase (reteplase); Boehringer Mannheim Corporation; Treatment for patients suffering from heart attack, Approved November 1996

Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel; Treatment for hypertension, Approved October 1996

Tiazac (diltiazem hydrochloride); Forest Laboratories; Treatment for hypertension, Approved February 1996

Visipaque (iodixanol); Nycomed; Diagnostic contrast agent, Approved April 1996

Drugs Approved in 1995

Androderm (Testosterone Transdermal System); TheraTech; Treatment for primary and secondary hypogonadism, Approved on September 29, 1995

Corvert Injection (ibutilide fumarate injection); Pharmacia & Upjohn; Treatment for irregular contractions of the heart, Approved December 1995

Prinivil or Zestril (Lisinopril); Merck, Zeneca; Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995

Toprol-XL (metoprolol succinate); AstraZeneca; For the treatment of hypertension, angina pectoris and heart failure, Approved January 1995